AIATELLA

Helsinki-based AIATELLA, founded in 2022, is a medical technology firm focused on transforming cardiovascular diagnostics through artificial intelligence. The company was established by CEO Jack Parker, a biomedical scientist with a background in clinical research within the UK's National Health Service (NHS), and CTO Onni Eriksson, a Finnish entrepreneur with a technical background and experience leading a 3D design company. Parker's motivation was deeply personal, influenced by his father's heart attack and his firsthand observations of the inefficiencies and burnout among radiologists dealing with overwhelming volumes of medical images. The founders met at a hackathon in Helsinki, where they combined Parker's clinical insights with Eriksson's technical expertise to address the slow, manual process of analyzing medical scans.

AIATELLA's core offering is its Automated Image Measurement (AIM) technology, a cloud-based software platform that automates the analysis of cardiovascular images from MRI, CT, and ultrasound scans. This system uses computer vision and deep learning algorithms to detect and quantify abnormalities, measure vessel dimensions, and track changes over time, reducing a process that can take a specialist up to an hour of manual work to just a few minutes. The technology is designed to be hardware-agnostic, ensuring it can work with imaging equipment from various manufacturers in different clinical settings. By automating these repetitive measurements, the platform allows clinicians to dedicate more time to complex interpretation and patient care. The company is also developing a portable, ultrasound-based screening device to enable mass preventative screening for cardiovascular diseases in diverse settings.

The firm operates on a B2B model, targeting hospitals, imaging centers, and healthcare providers as its primary clients. Revenue is generated through its software-as-a-service (SaaS) platform, which integrates into existing hospital Picture Archiving and Communication Systems (PACS) to support clinical workflows. The company is actively engaged in pilot programs and clinical trials with hospitals in the UK, USA, and with private healthcare company Pihlajalinna in Finland. In June 2025, AIATELLA secured €2 million in a seed funding round led by Nordic Science Investments, with participation from Specialist VC, Harjavalta Ventures, and Business Finland, to finance clinical trials and pursue regulatory approvals in Europe and North America.

Keywords: cardiovascular imaging, medical AI, radiology automation, preventative medicine, diagnostic software, automated image analysis, MedTech, vascular imaging, clinical workflow, preventative screening